This phase II trial was performed to evaluate the efficacy of a new @entity1261 ( @entity1261 )-supported multi-agent chemotherapy protocol, LSG15, for @entity146 @entity6494 ( @entity6494 ). Ninety-six previously untreated @entity1 with @entity146 @entity6494 were enrolled and grouped as: acute type (58), @entity706 type (28) and unfavourable chronic type (10). Therapy consisted of seven cycles of VCAP ( @entity1891 , @entity786 , @entity632 and @entity229 ), @entity860 ( @entity632 , @entity10848 and @entity229 ) and VECP ( @entity7324 , @entity2879 , @entity3003 and @entity229 ). @entity1261 was administered during the intervals between chemotherapy until neutrophil reconstitution was achieved. Eighty-one per cent of the 93 eligible @entity1 responded [95% confidence interval (CI), 71.1-88.1%], with 33 @entity1 obtaining complete response (35.5%) and 42 obtaining partial response (45.2%). The @entity1349 ( @entity1349 ) after registration was 13 months and the median follow-up duration of the 20 surviving @entity1 was 4.2 years (range 2.8-5.6). Overall survival at 2 years was estimated to be 31.3% (95% CI, 22.0-40.5%). Grade 4 haematological @entity137 of @entity1398 and @entity882 were observed in 65.3% and 52.6% of the @entity1 respectively, but grade 4 non-haematological @entity137 was observed in only one @entity1 . LSG15 is feasible with mild non-haematological @entity137 and improved the clinical outcome of @entity6494 @entity1 . @entity1349 and overall survival at 2 years were superior to those obtained by our previous trials.

A new XXXX -supported combination chemotherapy, LSG15, for @entity6494 : Japan Clinical Oncology Group Study 9303.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony-stimulating factor', 'G-CSF'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity7324 :: ('MESH:D014751', 'Chemical') :: ['vindesine'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity10848 :: ('MESH:C020766', 'Chemical') :: ['ranimustine'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity6494 :: ('MESH:D015459', 'Disease') :: ['adult T-cell leukaemia-lymphoma', 'ATL'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity860 :: ('MESH:D000249', 'Chemical') :: ['AMP'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['MST', 'median survival time']
@entity1261 :: (1440,Gene) :: ['G-CSF']
